Sociedad Americana de Hirudoterapia

Impact of the number of veins repaired in short-term digital replantation survival rate

Retrospective cohort published in JPRAS (2015)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosEfanov JI et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2015

Abstract

BACKGROUND: Venous congestion/insufficiency plays a major role in failure of finger replantation. Despite acceptable salvage rates with postoperative anticoagulation or leeching, operative technique remains the most important predictor of success. However, there are no indications in the literature on the benefit of anastomosing single versus multiple veins. METHODS: A retrospective review of finger amputations from 2011 to 2013 was conducted. The analyzed endpoint was the finger survival rate at discharge depending on the number of veins repaired: multiple veins (group 1), only one vein (group 2), or no veins (group 3). Proportions were compared using v2 tests/Fisher's exact tests; p-value <0.05 was considered significant. RESULTS: Seventy-two patients with complete digital amputation were operated including 101 fingers. Twenty-seven fingers (26.7%) failed before hospital discharge, with 78% of failures due to venous complications versus 22% with an arterial etiology. Group 2 had 15 replantation failures due to venous causes as opposed to only one from group 1, representing a 1.27-fold (95% confidence interval (CI): 0.99, 1.34) increased relative risk of failure (p = 0.032). Similarly, five fingers from group 3 suffered venous complications, resulting in a 1.49-fold (95% CI: 1.02, 1.73) increased likelihood of failure in comparison to group 1 (p = 0.008). No significant difference was observed between having only one vein repaired versus none (RR: 1.1792, 95% CI: 0.83, 2.10, p = 0.502). CONCLUSION: Efforts toward favoring two-vein repair lead to better survival of the replanted fingers. More cases need to be analyzed before formulating conclusions on specific levels of amputation with regard to venous anastomoses.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdolescentAdultAgedAged, 80 and overAmputation, TraumaticAnastomosis, SurgicalFemaleFinger InjuriesFingersFunctional LateralityHumansMale

Resumen

Across 72 patients and 101 finger replantations, 78% of failures were due to venous complications; two-vein repair was associated with significantly higher survival than single-vein repair, helping define when leech adjunct is most needed.

Por qué esto importa para la hirudoterapia

This retrospective study examined the impact of the number of veins repaired on short-term survival rates in 101 replanted fingers across 72 patients, finding that repairing multiple veins yielded significantly better survival compared to single-vein or no-vein repair, with venous complications accounting for 78% of failures. Leeching is mentioned in the background as one salvage option for venous congestion, but the study's focus is on surgical technique. For ASH, this is only indirectly relevant—the abstract does not report leech therapy outcomes, indications, or effectiveness, and leeching is referenced only in passing as a postoperative adjunct. The study's value to ASH is limited to contextualizing venous congestion as a major cause of replant failure, a problem for which hirudotherapy is sometimes employed.

Citación

Impact of the number of veins repaired in short-term digital replantation survival rate.

Efanov JI et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2015

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.